3750 Stock Overview
Cytori Cell Research Institute, Inc., engages in the research, development, production, and sale of cell therapy related medical devices in Japan.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Cytori Cell Research Institute, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | JP¥947.00 |
| 52 Week High | JP¥1,320.00 |
| 52 Week Low | JP¥730.00 |
| Beta | 0.56 |
| 1 Month Change | -0.63% |
| 3 Month Change | -14.07% |
| 1 Year Change | -15.30% |
| 3 Year Change | -31.77% |
| 5 Year Change | 110.44% |
| Change since IPO | -85.99% |
Recent News & Updates
Shareholder Returns
| 3750 | JP Real Estate | JP Market | |
|---|---|---|---|
| 7D | -0.3% | 1.8% | 1.4% |
| 1Y | -15.3% | 49.4% | 28.4% |
Return vs Industry: 3750 underperformed the JP Real Estate industry which returned 49.4% over the past year.
Return vs Market: 3750 underperformed the JP Market which returned 28.4% over the past year.
Price Volatility
| 3750 volatility | |
|---|---|
| 3750 Average Weekly Movement | 2.8% |
| Real Estate Industry Average Movement | 4.4% |
| Market Average Movement | 4.1% |
| 10% most volatile stocks in JP Market | 8.1% |
| 10% least volatile stocks in JP Market | 2.3% |
Stable Share Price: 3750 has not had significant price volatility in the past 3 months.
Volatility Over Time: 3750's weekly volatility (3%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2004 | 64 | Yoshihiro Hoshino | www.cytori.co.jp |
Cytori Cell Research Institute, Inc., engages in the research, development, production, and sale of cell therapy related medical devices in Japan. The company sells cell therapy kits, as well as engages in the research and development of cell therapy technology, etc. Its products pipeline includes ECCI-50 for the treatment of male stress urinary incontinence and liver cirrhosis; and Cyt-006 to prevent postoperative adhesion for primary rectal cancer. The company is also conducting clinical trials/research on cell therapy for a range of diseases and applications, including anterior cruciate ligament repair, bone repair, burn scars, chronic wound healing, critical limb ischemia, anal and Crohn’s disease fistulas, erectile dysfunction, etc. It also invests in, owns, develops, leases, and manages real estate projects and hotels; and provides real estate brokerage services.
Cytori Cell Research Institute, Inc. Fundamentals Summary
| 3750 fundamental statistics | |
|---|---|
| Market cap | JP¥8.46b |
| Earnings (TTM) | -JP¥889.00m |
| Revenue (TTM) | JP¥1.90b |
4.4x
P/S Ratio-9.5x
P/E RatioIs 3750 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 3750 income statement (TTM) | |
|---|---|
| Revenue | JP¥1.90b |
| Cost of Revenue | JP¥394.00m |
| Gross Profit | JP¥1.51b |
| Other Expenses | JP¥2.40b |
| Earnings | -JP¥889.00m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 14, 2024
| Earnings per share (EPS) | -99.57 |
| Gross Margin | 79.31% |
| Net Profit Margin | -46.69% |
| Debt/Equity Ratio | 369.0% |
How did 3750 perform over the long term?
See historical performance and comparison